Telaprevir with peginterferon/ribavirin for retreatment of null responders with advanced fibrosis post-orthotopic liver transplant.

@article{Kwo2014TelaprevirWP,
  title={Telaprevir with peginterferon/ribavirin for retreatment of null responders with advanced fibrosis post-orthotopic liver transplant.},
  author={Paul Y. Kwo and Marwan S. Ghabril and Marco A. Lacerda and Alfred Joseph Tector and Jonathan A Fridell and R. S. F. Vianna},
  journal={Clinical transplantation},
  year={2014},
  volume={28 6},
  pages={722-7}
}
INTRODUCTION Aggressive recurrence of hepatitis C remains problematic post-orthotopic liver transplant (OLT). There are limited data on treatment of HCV infection with telaprevir/boceprevir therapy with peginterferon/ribavirin (PR) post-OLT. AIM To review our experience with telaprevir addition to peginterferon/ribavirin in treatment of aggressive hepatitis C in null responders to PR post-OLT. METHODS Adult patients with recurrent HCV infection post-OLT with null response to peginterferon… CONTINUE READING
2 Citations
20 References
Similar Papers

References

Publications referenced by this paper.
Showing 1-10 of 20 references

Early virologic response in patients with HCV recurrence after liver transplant treated with triple therapy: a single center experience. Gastroenterology 2012;142:S-931

  • PS MANTRY, A MUBARAK, JS WEINSTEIN
  • 2012
1 Excerpt

Safety of telaprevir or boceprevir in combination with peginterferon alfa/ribavirin, in cirrhotic non responders. First results of the French early access program (ANRS CO20-CUPIC)

  • C HEZODE, C DORIVAL, F ZOULIM
  • J Hepatol 2012;56(Suppl
  • 2012
1 Excerpt

patients with hepatitis C virus : a 12 - week pilot study providing safety and efficacy data

  • A COILLY, B ROCHE, J DUMORTIER
  • 2012

Similar Papers

Loading similar papers…